AbCellera Biologics
ABCL
ABCL
127 hedge funds and large institutions have $370M invested in AbCellera Biologics in 2025 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 36 increasing their positions, 44 reducing their positions, and 18 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
127
Holders Change
–
Holders Change %
0%
% of All Funds
1.7%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
20
Increased
36
Reduced
44
Closed
18
Calls
$3.46M
Puts
$1.81M
Net Calls
+$1.65M
Net Calls Change
+$1.89M
Top Buyers
| 1 |
Millennium Management
New York
|
+$8.67M |
| 2 |
Two Sigma Advisers
New York
|
+$4.89M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$3.69M |
| 4 |
Two Sigma Investments
New York
|
+$3.38M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$1.71M |
Top Sellers
| 1 |
UBS AM
Chicago,
Illinois
|
-$24.7M |
| 2 |
VOYA Investment Management
Atlanta,
Georgia
|
-$23.7M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
-$6.28M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$5.61M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$3.07M |
